Firazyr
Bradykinin B2 receptor antagonist
Approved to treat acute attacks of Hereditary Angioedema (HAE) in adults 18 years and older.
Report side effects/adverse events at 1-800-FDA-1088.
Andembry
Activated Factor XII (FXIIa) inhibitor (monoclonal antibody)
Approved to prevent attacks of Hereditary Angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Report side effects/adverse events at 1-866-915-6958.
Berinert
C1 Esterase Inhibitor (Human)
Approved to treat acute abdominal or facial or laryngeal attacks of Hereditary Angioedema (HAE) in adult and adolescent patients.
Report side effects/adverse events at 1-866-915-6958.
Haegarda
C1 Esterase Inhibitor (Human)
Approved to treat Hereditary Angioedema (HAE) attacks in adolescent and adult patients.
Report side effects/adverse events at 1-866-915-6958.
Ruconest
C1 Esterase Inhibitor (Recombinant)
Approved to treat acute attacks in adult and adolescent patients with Hereditary Angioedema (HAE).
Report side effects/adverse events at 1-800-508-0024.
Cinryze
C1 Esterase Inhibitor (Human)
Approved to treat against angioedema attacks in patients with Hereditary Angioedema (HAE).
Report side effects/adverse events at 1-877-825-3327.
Newest NAC members bring geriatric and pediatric expertise
July 15, 2025
Read article
Statement on H.R. 1: Medicaid cuts threaten vulnerable patients
July 09, 2025
Read statement
Octapharma Plasma
The family-owned company, Octapharma AG, was established in 1983 with a single idea: that people with Hemophilia deserve access to better treatments.
Jerry Winkelstein helped build IDF’s respected reputation
July 02, 2025
Read article
